Trial Profile
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2021
Price :
$35
*
At a glance
- Drugs AGS 16C3F (Primary) ; Axitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Agensys; Astellas Pharma; Astellas Pharma Global Development
- 17 May 2021 Status changed from active, no longer recruiting to completed.
- 03 Mar 2020 Planned End Date changed from 1 Sep 2021 to 1 Sep 2020.
- 02 Aug 2019 Planned End Date changed from 1 Jun 2019 to 1 Sep 2021.